292 related articles for article (PubMed ID: 22645095)
1. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
Meany H; Dombi E; Reynolds J; Whatley M; Kurwa A; Tsokos M; Salzer W; Gillespie A; Baldwin A; Derdak J; Widemann B
Pediatr Blood Cancer; 2013 Jan; 60(1):59-64. PubMed ID: 22645095
[TBL] [Abstract][Full Text] [Related]
2. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.
Tsai LL; Drubach L; Fahey F; Irons M; Voss S; Ullrich NJ
J Neurooncol; 2012 Jul; 108(3):469-75. PubMed ID: 22407214
[TBL] [Abstract][Full Text] [Related]
3. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [
Azizi AA; Slavc I; Theisen BE; Rausch I; Weber M; Happak W; Aszmann O; Hojreh A; Peyrl A; Amann G; Benkoe TM; Wadsak W; Kasprian G; Staudenherz A; Hacker M; Traub-Weidinger T
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28771999
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
[TBL] [Abstract][Full Text] [Related]
6. False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of neurofibromatosis type 1.
Shahid KR; Amrami KK; Esther RJ; Lowe VJ; Spinner RJ
J Surg Orthop Adv; 2011; 20(2):132-5. PubMed ID: 21838076
[TBL] [Abstract][Full Text] [Related]
7. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.
Urban T; Lim R; Merker VL; Muzikansky A; Harris GJ; Kassarjian A; Bredella MA; Plotkin SR
Clin Nucl Med; 2014 May; 39(5):e301-7. PubMed ID: 24152623
[TBL] [Abstract][Full Text] [Related]
8. The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.
Higham CS; Dombi E; Rogiers A; Bhaumik S; Pans S; Connor SEJ; Miettinen M; Sciot R; Tirabosco R; Brems H; Baldwin A; Legius E; Widemann BC; Ferner RE
Neuro Oncol; 2018 May; 20(6):818-825. PubMed ID: 29409029
[TBL] [Abstract][Full Text] [Related]
9. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours.
Cardona S; Schwarzbach M; Hinz U; Dimitrakopoulou-Strauss A; Attigah N; Mechtersheimer section sign G; Lehnert T
Eur J Surg Oncol; 2003 Aug; 29(6):536-41. PubMed ID: 12875862
[TBL] [Abstract][Full Text] [Related]
11. Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/longitudinal study.
Nishida Y; Ikuta K; Ito S; Urakawa H; Sakai T; Koike H; Ito K; Imagama S
Cancer Sci; 2021 Mar; 112(3):1114-1122. PubMed ID: 33415792
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions.
Akshintala S; Baldwin A; Liewehr DJ; Goodwin A; Blakeley JO; Gross AM; Steinberg SM; Dombi E; Widemann BC
Neuro Oncol; 2020 Sep; 22(9):1368-1378. PubMed ID: 32152628
[TBL] [Abstract][Full Text] [Related]
13. Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.
Salamon J; Mautner VF; Adam G; Derlin T
Rofo; 2015 Dec; 187(12):1084-92. PubMed ID: 26333104
[TBL] [Abstract][Full Text] [Related]
14. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.
Warbey VS; Ferner RE; Dunn JT; Calonje E; O'Doherty MJ
Eur J Nucl Med Mol Imaging; 2009 May; 36(5):751-7. PubMed ID: 19142634
[TBL] [Abstract][Full Text] [Related]
15. Association between benign and malignant peripheral nerve sheath tumors in NF1.
Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
Reinert CP; Schuhmann MU; Bender B; Gugel I; la Fougère C; Schäfer J; Gatidis S
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
[TBL] [Abstract][Full Text] [Related]
17. Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.
Uthoff J; De Stefano FA; Panzer K; Darbro BW; Sato TS; Khanna R; Quelle DE; Meyerholz DK; Weimer J; Sieren JC
J Neuroradiol; 2019 May; 46(3):179-185. PubMed ID: 29958847
[TBL] [Abstract][Full Text] [Related]
18. Association of plexiform and diffuse neurofibromas with malignant peripheral nerve sheath tumor in NF I patients: a whole-body MRI assessment.
Attia S; Guirguis M; Le LQ; Chhabra A
Skeletal Radiol; 2024 Apr; 53(4):769-777. PubMed ID: 37903998
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
Chirindel A; Chaudhry M; Blakeley JO; Wahl R
J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of
Cook GJR; Lovat E; Siddique M; Goh V; Ferner R; Warbey VS
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1845-1852. PubMed ID: 28589254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
